



# Q2 2022 Investor Presentation

August 2022

SFE  
LISTED  
NYSE

# Forward-looking Statements

---



Statements made in this presentation include forward-looking statements, and those statements are subject to risks and uncertainties, which include, but are not limited to, Safeguard's ability to make good decisions about the monetization of our ownership interests for maximum value, or at all, and the return of value to our shareholders, our ability to complete a strategic transaction on desirable terms, or at all, the ongoing support of our existing ownership interests, the fact that our ownership interests may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of any publicly traded ownership interests, competition, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's ownership interests operate, including the impact of COVID-19, and other uncertainties described in our filings with the SEC. Many of these factors are beyond Safeguard's ability to predict or control. As a result of these and other factors, Safeguard's past financial performance should not be relied on as an indication of future performance. We encourage you to read Safeguard's filings with the SEC, including our Form 10-K, which describe in detail the risks and uncertainties associated with managing our business. Safeguard does not assume any obligation to update any forward-looking statements made in this presentation.

# Safeguard Scientifics, Inc. Overview



- Attractive late-stage venture portfolio in primarily tech-enabled healthcare companies
  - Seven tech-enabled healthcare companies, one marketing tech, and one fintech
  - 1.3mm shares in publicly traded Bright Health Group (ticker: BHG)
  - Portfolio has limited remaining follow-on capital needs
  
- Pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value
  - Strict portfolio management and capital allocation approach to follow-on deployments and exits decisions
  - Asset sale proceeds during 2021 totaled \$60.8 million
  - Since adoption of current strategy in January 2018, realized approximately \$257 million in cash proceeds
  
- Substantial progress towards returning capital to shareholders
  - Announced \$3 million open market share repurchase plan in March 2022
  - Repurchased over 400,000 shares on the open market at an average of \$4.59, totaling \$1.9 million for the year-to-date period
  
- Continue to reduce corporate costs and increase operating flexibility
  
- Committed to exploring all actions to maximize shareholder value
  - Engaged Houlihan Lokey as financial advisor in March 2022 to explore strategic alternatives
  
- Management and Board compensation aligned with shareholders' interests

# Companies by Revenue Stage



No pre-revenue  
companies



Proven business  
models




Maturing  
portfolio



Note: trailing twelve-month revenues as of 3/31/2022, reflects one quarter reporting lag.

# Aggregate Portfolio Revenue

TTM through March 31, 2022



**Note:** SFE reports the revenue of its companies on a one-quarter lag basis. Revenue for all years has been revised to exclude companies that were exited or fully impaired.

Certain amounts in 2018 and 2019 have also been adjusted to reflect the impact of revenue accounting changes adopted at applicable companies.

- **Aggregate portfolio revenue for the twelve months ending 3/31/2022 increased 14.1% year-on-year**

*Note: Trailing twelve-month revenues as of 3/31/2022, reflects one quarter reporting lag; excludes Flashtalking, MediaMath and Bright Health Group.*

# Portfolio Considerations



- Safeguard Market Cap < Fair Market Value < Projected Future Portfolio Exit Values
  - **Carrying value does not equal Fair Market Value due to equity method accounting**
  - **Fair Market Values calculated from widely accepted methodologies - recent third-party financings, company performance and public markets data, among others**
  - **Projected Future Portfolio Exit Values based on sector, company execution, capital availability, and future M&A assumptions**
  - **Recent public market peer group for tech-enabled healthcare trade at ~3.8x 2022 consensus revenues**
- Strict portfolio management and capital allocation philosophy to optimize value-maximization and time to exit
- Pursue multiple avenues to achieve exits
- Company sales or IPOs (“natural exit”) are the preferred approaches to maximize value
  - **Board influence to accelerate exit processes**
  - **Also explore secondary and structured transactions for specific situations**
- Engaged Houlihan Lokey as financial advisor in March 2022 to explore strategic alternatives

# Financial Matters



- As of June 30, 2022, no debt and \$17.5 million of cash, cash equivalents and restricted cash
  - **Repurchased \$1.9 million of common shares year-to-date**
- Continuing to return value to shareholders as additional exits occur above targeted liquidity level of \$18mm
- Follow-on funding to support companies has declined: \$9.2 million in 2020; \$2.7 in 2021
  - **Year-to-date deployments in 2022 have totaled \$5.0 million and we expect the remainder of the year to result in deployments towards the upper half of our initial range of \$5 million to \$9 million for 2022**
  - **Compared to \$17 million in 2019 and \$16 million in 2018**
- Continuing to reduce corporate expenses\*:
- \$0.8 million for the quarter ended June 30, 2022, as compared to \$1.0 million for comparable 2021 quarter – a 13% decline
  - **Expected to be at the low end or below the previously discussed range of \$3.5 - \$4.0 million for the year, exclusive of strategic transaction related expenses**
- Safeguard has ~\$367 million of Tax NOLs & Carryforwards
- Management and Board compensation aligned with shareholders' interest
  - **Board compensation is 100% equity**
  - **CEO compensation weighted to equity and performance**

\* Corporate expense is a non-GAAP measure that represents general and administrative expenses excluding depreciation, stock-based compensation, severance and retirement costs, and other non-recurring items.

# Key Financial Measures



	June 30, 2022	December 31, 2021	December 31, 2020
Cash, equivalents, restricted cash and marketable securities	\$17,535	\$24,764	\$15,601
Total Borrowings	\$0	\$0	\$0
Net Cash Position	+\$17,535	+\$24,764	+\$15,601
# of Ownership Interests *	9	10	14
General and administrative expenses (YTD)	\$2,380	\$7,153	\$9,466
Corporate expense (YTD) **	\$1,676	\$3,865	\$5,216

\* This count excludes Bright Health Group as well as companies within the Other ownership interests portion included in our quarterly results release.

\*\* Corporate expense is a non-GAAP measure that represents general and administrative expenses excluding depreciation, stock-based compensation, severance and retirement costs, and other non-recurring items.



# Safeguard Scientifics, Inc. Overview



- Attractive late-stage venture portfolio in primarily tech-enabled healthcare companies
  - Seven tech-enabled healthcare companies, one marketing tech, and one fintech
  - 1.3mm shares in publicly traded Bright Health Group (ticker: BHG)
  - Portfolio has limited remaining follow-on capital needs
- Pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value
  - Strict portfolio management and capital allocation approach to follow-on deployments and exits decisions
  - Asset sale proceeds during 2021 totaled \$60.8 million
  - Since adoption of current strategy in January 2018, realized approximately \$257 million in cash proceeds
- Substantial progress towards returning capital to shareholders
  - Announced \$3 million open market share repurchase plan in March 2022
  - Repurchased over 400,000 shares on the open market at an average of \$4.59, totaling \$1.9 million for the year-to-date period
- Continue to reduce corporate costs and increase operating flexibility
- Committed to exploring all actions to maximize shareholder value
  - Engaged Houlihan Lokey as financial advisor in March 2022 to explore strategic alternatives
- Management and Board compensation aligned with shareholders' interests



# Appendix

**SFE**  
**LISTED**  
**NYSE**

# Ownership Interests at June 30, 2022



Partner Companies	Stage	Category	Acquisition Year	Primary / Fully Diluted ** Ownership %	Carrying Value * (in millions)	Cost (in millions)
Aktana, Inc.	Rev. \$20M - \$50M	Healthcare	2016	13.4% / 11.4%	\$ -	\$ 15.9
Clutch Holdings, Inc.	Rev. \$10M - \$20M	Digital Media	2013	41.7% / 33.2%	5.1	18.3
InfoBionic, Inc.	Rev. \$10M - \$20M	Healthcare	2014	25.2% / 22.1%	-	22.0
Lumesis, Inc.	Rev. \$5M - 10M	Financial Services	2012	43.2% / 43.3%	1.5	5.6
meQuilibrium	Rev. \$10M - \$20M	Healthcare	2015	31.5% / 22.1%	0.6	14.0
Moxe Health Corporation	Rev. \$5M - \$10M	Healthcare	2016	19.4% / 18.4%	8.1	7.5
Prognos Health, Inc.	Rev. \$20M- \$50M	Healthcare	2011	28.5% / 24.7%	3.0	14.6
Syapse, Inc.	Rev. \$10M - \$20M	Healthcare	2014	11.0% / 8.8%	3.2	25.0
TriceMedical, Inc.	Rev. \$20M - \$50M	Healthcare	2014	12.6% / 9.0%	0.6	11.8
Bright Health Group	Rev. \$50M+		2021	n/a	2.4	-
All others	Various			n/a	1.1	19.7
<b>TOTAL:</b>					<b>\$ 25.6</b>	<b>\$ 154.4</b>

\* Carrying value is determined under the Equity method of accounting for those assets which meet that criteria and the Other method for the remaining assets. See our Annual Report on Form 10K for a description of each method.

\*\* Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction related obligations in a liquidation or exit transaction.

# Condensed Consolidated Balance Sheets



	June 30, 2022	December 31, 2021
<b>Assets</b>		
Cash, cash equivalents, restricted cash	\$ 17,535	\$ 24,764
Ownership interests	2,407	4,549
Other current assets	1,126	965
Total current assets	21,068	30,278
Ownership interests in and advances	23,192	21,972
Other assets	1,698	1,778
<b>Total Assets</b>	<b>\$ 45,958</b>	<b>\$ 54,028</b>
<b>Liabilities and Equity</b>		
Other current liabilities	\$ 1,142	\$ 1,734
Total current liabilities	1,142	1,734
Lease liability - non-current	1,471	1,678
Other long-term liabilities	50	50
Total equity	43,295	50,566
<b>Total Liabilities and Equity</b>	<b>\$ 45,958</b>	<b>\$ 54,028</b>

*In thousands*

# Income Statement



	Three Months Ended June 30,		Six Months Ended June 30,	
	2022	2021	2022	2021
Operating expenses	\$ 1,146	\$ 1,991	\$ 2,380	\$ 4,454
Operating loss	(1,146)	(1,991)	(2,380)	(4,454)
Other income (loss), net	30	6,733	(1,967)	7,439
Interest, net	145	74	246	127
Equity income (loss), net	1,454	(5,136)	(2,125)	14,193
Net income (loss) before income taxes	483	(320)	(6,226)	17,305
Income tax benefit (expense)	—	—	—	—
<b>Net income (loss)</b>	<b>\$ 483</b>	<b>\$ (320)</b>	<b>\$ (6,226)</b>	<b>\$ 17,305</b>
Net income (loss) per share:				
<b>Basic</b>	<b>\$ 0.03</b>	<b>\$ (0.02)</b>	<b>\$ (0.38)</b>	<b>\$ 0.83</b>
<b>Diluted</b>	<b>\$ 0.03</b>	<b>\$ (0.02)</b>	<b>\$ (0.38)</b>	<b>\$ 0.83</b>
Weighted average shares used in computing income (loss) per share:				
Basic	16,356	20,856	16,468	20,879
Diluted	16,356	20,856	16,468	20,879

*In thousands, except per-share amounts*

# Aktana—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Sales Decision Support / Marketing Automations (Life Sciences / Medtech)

**Headquarters:** San Francisco, CA

**CEO:** David Ehrlich

- Aktana is an AI-enabled life sciences marketing decision support solution that helps sales and marketing teams to optimize go-to-market strategies at the brand level
- Helps customers improve their commercial effectiveness by delivering data-driven insights and suggestions directly to sales reps, coordinating multi-channel actions, and providing insight regarding which strategies work best for customers
- Aktana’s Decision Support System (“DSE”) provides next-best-action insights for sales reps, while the Learning Platform allows the engine to learn which suggestions are optimal

## THESIS

- Total addressable market is approximately \$2B for pharma and biotech sales rep decision support
- Focus on the life sciences market has contributed to robust multi-year growth rates with over half of the world’s top 15 pharmaceutical companies
- Real-world validation and proven ROI across therapeutic categories and geographies
- Robust partner ecosystem
- Serves brands across a range of therapeutic areas in multiple geographies

## SUMMARY

**Origin:** June 2016

**Capital:** \$15.9M

**Ownership:** 13% Primary / 11% Fully Diluted

**Financing Rounds:** Series A, Series B, Series C, Series D, Convertible Notes

**Other Investors:** Leerink Transformation Partners, Novartis (dRx), HLM Venture Partners, Norwest, Starfish Ventures

**Board Member:** Eric Salzman

## REVENUE MODEL

Aktana prices its platform separately for the decision support engine (DSE) (aka top layer)—which provides smart suggestions and insights to pharmaceutical sales representatives within their workflow to help them make better everyday decisions—and the Learning Platform (bottom layer). For DSE, Aktana licenses the software based on a per rep per brand basis according to size and number of reps. For the Learning Platform, Aktana charges an annual fee.

## COMPETITORS

Veeva, Salesforce, IQVIA, ZS Associates, Vymo, Customer Insourcing

# Clutch—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Customer Rewards and Loyalty

**Headquarters:** Ambler, PA

**CEO:** Ned Moore

- A leading wholistic solution to a fragmented industry, Clutch offers customer relationship management and a mobile commerce platform that unifies gifting, loyalty and shopping to bring the most relevant information to consumers and the most targeted customers to merchants
- The Company offers a marketing platform that serves as a customer hub delivering deep intelligence, derived from real-time behaviors and transactions across in-store, online, mobile and social channels
- Revenue is comprised of four components: contracted recurring, transactional, services and marketing. The majority of revenue is derived from transaction-based services. Clutch also earns a small portion via on-boarding fees and is looking at the data monetization potential

## THESIS

- The consumer and loyalty management market is focused on delivering to premier brands the ability to maximize relationships with their customers along with lifetime value and is estimated to reach a value of \$6.8Bn by 2023, representing a 5-year CAGR of 21.1% from 2018
- Broad potential client base includes any consumer business that uses gift and loyalty programs
- Well positioned to unify the very fragmented, non-standardized set of rewards and loyalty solutions utilized today across major brands, and to execute on strategic and referral partnerships to drive growth
- Expanding into new verticals, such as banking and financial services, food, hospitality and healthcare, which help balance cyclicity in the core verticals and have higher average order value

## SUMMARY

**Origin:** February 2013

**Capital:** \$18.3M

**Ownership:** 42% Primary / 33% Fully Diluted

**Financing Rounds:** Series A, Series B, SAFE Notes, Convertible Notes

**Other Investors:** NewSpring Capital, Ben Franklin Technology Partners, Empactful, Sierra

**Board Member:** Eric Salzman

## REVENUE MODEL

The majority of Clutch's revenue is transaction-based, while a small portion is via on-boarding fees. Strategic channel partners and other customers include any consumer business that uses gift and loyalty programs. Customers pay a transaction fee for users that use the loyalty and gifting features platform. The client is incentivized to onboard as many users onto the gifting and loyalty platform as it can, because this will ultimately lead to more transactions and purchases. Clutch believes there are also data monetization opportunities once the platform is integrated.

## COMPETITORS

Crowdtwist, Cheetah Digital, Session M

# InfoBionic—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Patient Monitoring (Cardiac)

**Headquarters:** Boston, MA

**CEO:** Stuart Long

- A digital health company focused on creating superior patient monitoring solutions for chronic disease management with a market focus on cardiac arrhythmias
- Has 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for MoMe® Kardia, a wireless, remote monitoring system designed to aid physicians in their diagnosis of cardiac arrhythmia
- The proprietary software analyzes the data and flags incidents for physician review on a Web-based physician portal

## THESIS

- The global addressable market for monitoring cardiac arrhythmia and related events is estimated to be approximately \$3B worldwide, including \$1B in the U.S.
- Innovative SaaS revenue model, which includes an upfront device sale followed by a monthly subscription fee for unlimited use of the company’s cloud-based diagnostic service and portal
- MoMe® Kardia displaces IDTFs and redirects reimbursement economics to the ordering physicians, encouraging adoption

## SUMMARY

**Origin:** March 2014

**Capital:** \$22.0M

**Ownership:** 25% Primary / 22% Fully Diluted

**Financing Rounds:** Series C, Sub Debt

**Other Investors:** Eagle Investments, BCBS KS, Broadview Ventures, Excel Venture Management, HealthTechCapital, Zaffre Investments

**Board Member:** Eric Salzman

## REVENUE MODEL

One of InfoBionic’s most differentiated features is its SaaS revenue model, which includes an upfront device sale followed by a monthly subscription fee for unlimited use of the company’s cloud-based diagnostic service and portal.

## COMPETITORS

iRythm, BioTelemetry (Philips), AliveCor, Medi-Lynx, Zywie, Medtronic, Abbott, GE Healthcare, OSI Systems



# Lumesis—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Financial Analytics / Compliance

**Headquarters:** Stamford, CT

**CEO:** Gregg Bienstock

- Lumesis is a financial technology company focused on providing business efficiency and compliance solutions via its DIVER platform to hundreds of clients and over 45,000 users in the municipal bond marketplace
- The DIVER platform from Lumesis delivers technology and data solutions helping firms efficiently meet credit, regulatory and risk needs
- The Company's solutions enable portfolio managers, investment advisors, compliance professionals, financial advisor networks and issuers / underwriters to heat-map portfolios against local economic scenarios, benchmark against industry indices, manage their portfolios against internal credit and risk models, and monitor issuer disclosures

## THESIS

- The municipal bond market has doubled in size over the past 10 years, with over \$3.7 trillion of U.S. municipal debt outstanding among 45,000 unique issuers
- The Company is solely dedicated to the municipal bond market, which has been historically underserved by technology providers
- Works with over 200 institutional clients, blue-chip broker dealers, asset managers, insurance companies, mutual funds and rating agencies
- Only company that serves the entire municipal bond market, including buy-side, sell-side and legal / compliance
- Large IP portfolio and proprietary database create significant barriers to entry

## SUMMARY

<b>Origin:</b>	February 2012
<b>Capital:</b>	\$5.6M
<b>Ownership:</b>	43% Primary /43% Fully Diluted
<b>Financing Rounds:</b>	Series A, Series B
<b>Other Investors:</b>	Jim Ashton (JA3 Partners)
<b>Board Member:</b>	Mark Herndon, Steve Grenfell

## REVENUE MODEL

Lumesis licenses financial software products to the municipal fixed income market to be used as analytical and compliance tools. Customers buy licenses on an enterprise / per seat per issuance basis, usually covering an annual period. Lumesis also sells data to financial market participants.

## COMPETITORS

ValueLine, Inc., Fidessa Group plc, Reis, Inc., Envestnet, Inc., Forrester Research Inc., Financial Engines, Inc., DAC, Investment Technology Group, Inc., BLX, DPC Data, Refinitiv

# meQuilibrium—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Human Capital Management

**Headquarters:** Boston, MA

**CEO:** Jan Bruce

- SaaS-based proprietary resilience development solutions powered by predictive analytics and AI for organizations to manage their human capital and develop engaged, agile workforces
- The Company offers solutions for individual employees (Engage), managers and teams (Empower), and HR and Benefits managers (Gateway and Collaborate). Solutions are multi-modal and global
- The solution increases engagement, productivity, and performance and improved outcomes in retaining and developing top talent and managing stress, health, and well-being
- Its product suite is sold as a per-employee-per-year SaaS delivered in a desktop or mobile environment

## THESIS

- Human Capital Management (“HCM”) software market was estimated at \$23B in 2021 and is expected to grow at 9% CAGR through 2029
- Current customer base of over 40 Fortune 500 clients and in 60+ countries
- Contracts are 2-3 years with each year typically paid upfront by customers
- Demonstrable ROI within key early adopters, including Comcast, HP, and JPMorgan
- Emphasis on HCM (versus wellness) opens up new potential customers and strategic channel partners, maximizing topline growth potential
- Opportunity to maximize products being sold to a single customer (land and expand)



## SUMMARY

**Origin:** April 2015

**Capital:** \$14.0M

**Ownership:** 32% Primary / 22% Fully Diluted

**Financing Rounds:** Series A, Series B, Series C

**Other Investors:** HLM Venture Partners, Chrysalis Ventures

**Board Member:** Eric Salzman

## REVENUE MODEL

meQuilibrium’s product is sold as a PEPY software-as-a-service delivered in a desktop or mobile environment. Most current contracts are 2-3 years in length and each year is typically paid upfront by customers.

## COMPETITORS

Castlight Health (CSLT), Limeade, Happify, Headspace, Optum, Success Factors (SAP), Whil

1. Based on industry and market reports

# Moxe—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Interoperability

**Headquarters:** Madison, WI

**CEO:** Dan Wilson

- Provides a clinical data clearinghouse, creating a two-sided network facilitating the bi-directional exchange of clinical, analytic, and administrative data between health systems and payers
- Key product, Substrate, serves as an electronic medical record integration platform, facilitating the real-time exchange data between payers and their provider networks for risk adjustment and other use cases. Moxe's Digital ROI product, which automates all clinical release of information requests, is built on top of Substrate
- Moxe's second product, Convergence, creates a customer portal directly in the provider's EMR workflow, allowing payers to share data and actionable insights directly with physicians
- Currently developing additional products aimed at improving clinical data workflows for payer and health system customers

## THESIS

- Moxe plays in large and growing spaces; interoperability market is \$1.9B (7.4% CAGR); healthcare analytics market is \$8.9B (27% CAGR); value-based care / population health management software market is expected to reach \$32B by 2020
- Current market for chart retrieval estimated >\$300M; HCC reconciliation and risk adjustment larger (\$5B+) with significant incumbents; current processes slow and manual
- Moxe offers better, faster, cheaper solution with more complete data; multiple uses cases for payers, providers, pharma, and patients
- Opportunity to leverage network effects to accelerate scaling



## SUMMARY

**Origin:** September 2016

**Capital:** \$7.5M

**Ownership:** 19% Primary / 18% Fully Diluted

**Financing Rounds:** Series A, Series B

**Other Investors:** UPMC Enterprises, 3M Ventures, Piper Sandler Merchant Banking, Vensana Capital

**Board Member:** Eric Salzman

## REVENUE MODEL

Moxe has priced its solution on a per health system site basis and a transactional basis. Moving forward, Moxe is implementing PMPM pricing for payer customers by health system site to improve revenue predictability.

## COMPETITORS

Availity, Ciox, Experian, Innovaccer, Inovalon, McKesson Corporation, MRO Corp, Navinet (NantHealth)

# Prognos—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Healthcare Analytics / AI

**Headquarters:** New York, NY

**CEO:** Sundeep Bhan

- Prognos aggregates, harmonizes and analyzes clinical diagnostic data for life sciences, diagnostic companies, and payers, aiming to improve health by tracking and predicting disease
- The Prognos Registry of 22 billion clinical records for 200 million patients in over 50 disease areas enables earlier identification of patients who can benefit from enhanced treatment decision making and risk management
- The Company operates in two verticals – Life Sciences and Payers. In the Life Sciences segment, Prognos contracts with biopharma firms to identify patients who are candidates for drug treatment.
- In the Payer segment, Prognos contracts with plans for various population risk use cases annually and has revenue share agreements with labs to secure access to the data

## THESIS

- Large, unique clinical data asset; proprietary technology and data science/machine learning/AI capabilities; data network effects
- Multiple use cases applicable to pharma, payers, labs, and PBMs with potential for expansion into provider space
- Based on current monetization strategies, the total addressable healthcare analytics market for Prognos' products is estimated to reach \$5.5bn+
- Strategic partnership opportunities

## SUMMARY

**Origin:** November 2011

**Capital:** \$14.6M

**Ownership:** 29% Primary / 25% Fully Diluted

**Financing Rounds:** Series A, Series B, Series C, Convertible Notes

**Other Investors:** Hikma Ventures, Cigna Ventures, ARC Angel Fund, Merck GHIF, GIS Strategic Ventures (Guardian Life), Hermed Capital, Maywic Strategic Inv

**Board Member:** Eric Salzman

## REVENUE MODEL

Prognos operates in two verticals – Life Sciences and Payers. In the Life Sciences segment, Prognos has adopted a marketplace model whereby biopharma firms access specific data aggregated by Prognos on a per use basis. Broad range of applications including patient identification solutions. In the Payer segment, Prognos contracts with plans for various population risk use cases annually and has revenue share agreements with labs to secure access to the data.

## COMPETITORS

IQVIA, Health Verity, LabCorp, Quest, Symphony Health, Komodo Health

# Syapse—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Precision Medicine

**Headquarters:** San Francisco, CA

**CEO:** Ken Tarkoff

- Multi-sided platform creating a data network effect in order to improve the way cancer and other diseases are treated
  - Health systems contribute clinical and other data to the platform and receive clinical and business insights
  - Pharma, on the other side of the platform, purchases insights and delivers information back to health systems
- Syapse collects and networks data from siloed hospital and laboratory enterprise systems (Syapse Network) allows the Company to provide solutions for pharma including real world evidence generation, identification of patients for clinical trials and hub services
- Ecosystem partnerships with Pfizer, Amgen, others TBA

## THESIS

- Syapse is initially focused on oncology, opportunity to leverage the platform to other disease verticals
- Scalability allows targeting of large community health systems (50% of oncology pts in U.S) and ex-U.S, expansion
- \$9B U.S./\$15B Global market opp. from pharma partnerships and \$250M U.S./\$1B Global market opp. from health systems in oncology

## SUMMARY

**Origin:** June 2014

**Capital:** \$25.0M

**Ownership:** 11% Primary / 9% Fully Diluted

**Financing Rounds:** Series A, Series B, Series C, Series D, Series E, Series F, Series G

**Other Investors:** Amgen Ventures, Ascension Ventures, Intermountain Healthcare Innovation Fund, Merck GHIF, Medidata Ventures, Northpond Ventures, Revelation Partners, Social Capital

**Board Member:** Eric Salzman

## REVENUE MODEL

Syapse contracts with pharma and other ecosystem relationships via multi-year license agreements for products across RWE, clinical trial, regulatory, and commercial use cases.

## COMPETITORS

Flatiron Health, Cota, Tempus Health, Concert

# Trice—Company Overview



## COMPANY OVERVIEW

**Market Segment:** Medical Device

**Headquarters:** Malvern, PA

**CEO:** Mark Foster

- Pioneering disposable cameras and instruments that enable faster diagnostics and shift of low-risk procedures to the office and surgery center settings
- Trice Medical's FDA-approved 510(k)-cleared device, mi-eye 2, is a disposable, handheld 2.2mm arthroscope, consisting of a needle with an integrated camera and a light source designed for in-office diagnostics
- Camera and ultrasound (mi-Ultra) products help physicians with real-time analysis, faster treatment, and schedule patients for surgery immediately
- Endoscopic Carpal Tunnel Release (ECTR) kit includes surgical instruments and a mi-eye 2; kit allows physicians to perform procedures in the office
- IP for other indications including neurosurgery, ob-gyn, respiratory, ENT and veterinary

## THESIS

- mi-Eye addressable market (U.S.) is more than 8 million orthopedic-focused MRI exams which are conducted each year.
- Positive economics for payers and providers
- Carpal tunnel represents a growing market size with over 600K performed annually with a favorable market trend towards endoscopic (versus open) procedures
- Tenex Health (acquired by Trice) sells minimally invasive orthopedic products to address tendon pain
- Strong proprietary position provides the ability to enter additional verticals and partner/license.



## SUMMARY

**Origin:** July 2014

**Capital:** \$11.8M

**Ownership:** 13% Primary / 9% Fully Diluted

**Financing Rounds:** Series A, Series B, Series C, Series D

**Other Investors:** Charter Capital, BioStar Ventures, HealthQuest Capital, Michigan Employees Retirement System, Smith & Nephew, Bioventus

**Board Member:** Eric Salzman

## REVENUE MODEL

Trice sells the mi-eye cameras, ECTR kits, Tenex products, mi-Ultra, and companion tablets to physicians on a per-unit basis.

Trice also licenses its IP and services out to select large medtech firms for use cases Trice does not plan on pursuing independently.

## COMPETITORS

Arthrex, Karl Storz, Smith & Nephew, Stryker, Depuy Synthes, CONMED, Biomet-Zimmer, J&J



# Q2 2022 Investor Presentation

August 2022

SFE  
LISTED  
NYSE